Polyester Copolymer Drug Loading via Ester Bonding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biodegradable and biocompatible polymers face challenges in achieving high loading and controlled release of pharmaceutical compounds, particularly interleukin inhibitors, due to limited reactive sites and solvent compatibility issues, leading to low loading yields and unsustained release profiles.
Innovation Solution
The development of polyester copolymers formed by combining an alcohol-pharmaceutical conjugate with a polyol and an acid monomer, using methods that include heating and removing water to produce a polymeric material with high loading of pharmaceutical compounds, such as salicylic acid, which is incorporated into the polymer structure through ester bonds, allowing for a controlled release mechanism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional biodegradable polymers are used to deliver pharmaceutical compounds, then biocompatibility is maintained, but pharmaceutical loading levels remain low due to limited reactive sites
Solution Approach 1:
The polymer structure is segmented into multiple functional regions: hydrophobic domains for drug incorporation, reactive ester bond sites for pharmaceutical attachment, and biodegradable segments for controlled release. This segmentation allows high pharmaceutical loading while maintaining processable polymer characteristics.
Solution Approach 2:
The invention creates a composite polymer system combining hydrophobic and hydrophilic segments, reactive and inert regions, and biodegradable and structurally stable components. This composite approach enables simultaneous achievement of high drug loading, biocompatibility, and controlled release kinetics.
2Duration of action of moving object
If pharmaceutical compounds are incorporated into biodegradable polymers, then controlled release is achieved, but release profiles are unsustained due to rapid degradation
Solution Approach 1:
The polymer degradation rate is made dynamic and controllable through adjustable ester bond density and cross-linking degree. The system transitions from rapid initial degradation to sustained controlled degradation, matching the pharmaceutical release profile requirements and extending therapeutic action duration.
Solution Approach 2:
Key parameters including ester bond concentration, hydrophobic segment length, and cross-linking density are optimized to control degradation kinetics. These parameter adjustments enable sustained release profiles while maintaining biocompatibility and preventing premature drug release.
3Quantity of substance
If high loading of pharmaceutical compounds is achieved, then therapeutic efficacy is improved, but solvent compatibility issues arise during polymer synthesis
Solution Approach 1:
An intermediary step is introduced where pharmaceutical compounds are first activated or pre-complexed with facilitating agents before incorporation into the polymer matrix. This intermediary approach resolves solvent compatibility issues during synthesis while enabling high pharmaceutical loading in the final product.
Solution Approach 2:
Pharmaceutical compounds undergo preliminary processing including activation, protection group addition, or pre-complexation before polymer incorporation. This preliminary action ensures compatibility with polymer synthesis conditions and enables high loading levels without compromising the ease of manufacture.
4Productivity
If reactive sites are increased to improve pharmaceutical loading, then drug incorporation efficiency improves, but polymer stability and biocompatibility are compromised
Solution Approach 1:
Reactive sites are distributed non-uniformly throughout the polymer structure, with higher concentrations in specific regions designated for drug incorporation and lower concentrations in regions requiring structural stability. This local quality differentiation maintains both high drug incorporation efficiency and polymer reliability.
Solution Approach 2:
Different segments of the polymer are assigned different functional qualities: some segments provide reactive sites for drug attachment, while other segments maintain structural integrity and biocompatibility. This spatial differentiation of quality allows simultaneous optimization of productivity and reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting polyester-pharmaceutical copolymers achieve high loading levels of up to 25% pharmaceutical compounds by weight, maintaining similar physical and chemical characteristics to the pure polymer, with a sustained controlled release of the pharmaceutical compound through degradation, providing a therapeutic delivery system for interleukin inhibitors.
Implementation Method 1
The alcohol-pharmaceutical conjugate includes a pharmaceutical compound having at least one carboxyl group attached to the polyol by an ester bond
Implementation Method 2
combining an alcohol-pharmaceutical conjugate, a polyol, and an aqueous liquid in a vessel; adding an acid monomer to the vessel and heating and removing water from the vessel to produce the polymeric material
Implementation Method 3
heating and removing water from the vessel to produce the polymeric material
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method includes combining an alcohol-pharmaceutical conjugate, a polyol, and an aqueous liquid in a vessel. The alcohol-pharmaceutical conjugate includes a pharmaceutical compound having at least one carboxyl group attached to the polyol by an ester bond. The method also includes adding an acid monomer to the vessel and heating and removing water from the vessel to produce the polymeric material. The polymeric material includes a polyester copolymer of the acid monomer and the polyol and the pharmaceutical compound.